Oppenheimer Weighs in on Agios Pharmaceuticals, Inc.’s Q1 2023 Earnings (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIOGet Rating) – Analysts at Oppenheimer issued their Q1 2023 earnings per share estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, May 5th. Oppenheimer analyst M. Breidenbach expects that the biopharmaceutical company will post earnings per share of ($1.53) for the quarter. Oppenheimer also issued estimates for Agios Pharmaceuticals’ Q2 2023 earnings at ($1.50) EPS, Q3 2023 earnings at ($1.35) EPS and Q4 2023 earnings at ($1.31) EPS.

AGIO has been the subject of several other research reports. Canaccord Genuity Group reduced their price objective on shares of Agios Pharmaceuticals from $52.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, February 16th. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $61.00 to $67.00 and gave the stock an “outperform” rating in a research report on Friday, February 25th. HC Wainwright dropped their price target on shares of Agios Pharmaceuticals from $98.00 to $96.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. StockNews.com started coverage on shares of Agios Pharmaceuticals in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, The Goldman Sachs Group dropped their price target on shares of Agios Pharmaceuticals from $37.00 to $23.00 and set a “sell” rating on the stock in a research report on Monday, March 7th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $51.14.

AGIO stock opened at $22.62 on Monday. The company has a market capitalization of $1.24 billion, a P/E ratio of -3.51 and a beta of 1.51. The company has a 50-day simple moving average of $27.95 and a 200 day simple moving average of $32.66. Agios Pharmaceuticals has a fifty-two week low of $21.72 and a fifty-two week high of $62.15.

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, topping the consensus estimate of ($1.83) by $0.09. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $2.71 million. During the same period in the previous year, the company earned ($1.31) EPS.

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Horizon Advisors Inc. acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $33,000. Point72 Hong Kong Ltd increased its holdings in shares of Agios Pharmaceuticals by 214.6% in the 4th quarter. Point72 Hong Kong Ltd now owns 1,513 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,032 shares during the period. AGF Investments Inc. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $194,000. Envestnet Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at about $230,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $292,000.

Agios Pharmaceuticals Company Profile (Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Featured Stories

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.